Table 2 Secondary efficacy endpoints
Variables | Total (n = 63 ) | Placebo (n = 28) | Orlistat (n = 35) | P |
|---|---|---|---|---|
General data | ||||
Weight (kg) | -1.92 ± 2.59 | -0.76 ± 2.37 | -2.85 ± 2.37 | 0.001 |
BMI (kg/m2) | -0.63 ± 0.83 | -0.25 ± 0.75 | -0.95 ± 0.77 | 0.001 |
WC (cm) | -1.98 ± 2.67 | -0.75 ± 2.60 | -2.97 ± 2.32 | 0.001 |
Body fat (kg) | -1.39 ± 2.11 | -0.19 ± 1.69 | -2.30 ± 1.95 | <0.001 |
Body muscle (kg) | -0.42 ± 0.89 | -0.09 ± 0.87 | -0.67 ± 0.83 | 0.021 |
Patients with gout | 49 (77.78%) | 21 (75.00%) | 27 (77.14%) | 0.843 |
Blood chemistry parameters | ||||
Glucose (mmol/L) | -0.06 ± 0.50 | -0.03 ± 0.48 | -0.07 ± 0.53 | 0.776 |
HbA1c (%) | 0.00 (-0.20,0.10) | 0.00 (-0.10,0.19) | -0.10 (-0.30,0.10) | 0.259 |
HDL (mmol/L) | -0.05 ± 0.13 | 0.01 ± 0.13 | -0.09 ± 0.10 | 0.002 |
LDL (mmol/L) | -0.24 (-0.61,0.21) | 0.18 (-0.40,0.44) | -0.55 (-0.67, -0.14) | <0.001 |
TC (mmol/L) | -0.39 ± 0.75 | -0.10 ± 0.64 | -0.61 ± 0.76 | 0.012 |
TG (mmol/L) | -0.17 (-0.82,0.26) | -0.31 (-0.81,0.13) | -0.14 (-1.11,0.56) | 0.268 |
ALT (U/L) | -4.50 (-21.50,5.00) | -0.85 (-8.33,6.78) | -12.00 (-23.85,2.85) | 0.083 |
AST (U/L) | -1.20 (-7.30,3.20) | 0.20 (-2.35,4.20) | -2.80 (-7.85,1.35) | 0.172 |
Urea (mmol/L) | 0.20 (-0.40,0.80) | 0.30 (-0.43,0.83) | 0.10 (-0.35,0.75) | 0.609 |
Creatinine (µmol/L) | 0.03 ± 7.38 | 0.05 ± 7.02 | -0.01 ± 7.75 | 0.983 |
e-GFR (ml/min/1.73m2) | 0.38 ± 9.08 | 5.03 ± 22.52 | 0.50 ± 10.44 | 0.390 |
FINS (uU/ml) | -3.01 (-7.02,0.72) | -2.34 (-7.89,0.99) | -3.08 (-7.24,1.14) | 0.856 |
Fasting C peptide (ng/ml) | -0.59 (-1.35, -0.10) | -0.60 (-1.00, -0.090) | -0.55 (-1.79, -0.07) | 0.980 |
FibroScan | ||||
E (kPa) | -0.57 ± 1.34 | -0.12 ± 0.90 | -0.88 ± 1.52 | 0.029 |
CAP (dB/m) | -21.29 ± 32.66 | -7.86 ± 36.82 | -30.39 ± 26.42 | 0.013 |